Previous 10 | Next 10 |
Benefit corporations are a new form of business and increasing in number on the market. Similar to ESG metrics, these companies often take it many steps further in regards to positivity. The business structure allows some profits to be syphoned away towards beneficial endeavors, w...
Fresh campaign highlights Cooper Kupp’s experience with eye allergies and how Pataday can provide itch relief for millions of Americans with eye allergies 1 Partnership supports Pataday Once Daily Relief Extra Strength, the first 24-hour eye allergy itch relief drop...
Alcon continues to grow at a double-digit rate and is on track to achieve management's full-year guidance. Both the Surgical and the Vision Care segments delivered double-digit growth, which highlights a solid demand for the company's products in every category. While I belie...
Alcon (NYSE:ALC) has priced a public offering of EUR500M of its 2.375% senior notes due 2028. The notes will be issued by an indirect wholly-owned subsidiary Alcon Finance B.V. The offering is expected to close on May 31, 2022. Proceeds will be used for general corporate purposes, which may i...
Alcon Inc. (SIX/NYSE: ALC), today announced that it has commenced and priced a public offering of EUR 500 million aggregate principal amount of its 2.375% senior notes due 2028 (the “Notes”). The Notes will be issued by Alcon Finance B.V., Alcon Inc.’s indirect whol...
Expands ophthalmic eye drop portfolio leveraging market access expertise and newly created US ophthalmic eye drop sales force EYSUVIS complements Systane Preservative-Free by expanding treatment options for dry eye Alcon (SIX/NYSE: ALC), the global leader in eye ...
The following slide deck was published by Alcon Inc. in conjunction with their 2022 Q1 earnings call. For further details see: Alcon Inc. 2022 Q1 - Results - Earnings Call Presentation
Alcon Inc. (ALC) Q1 2022 Results Conference Call May 11, 2022 08:00 AM ET Company Participants Dan Cravens - VP, IR David Endicott - CEO Tim Stonesifer - CFO Conference Call Participants Daniel Buchta - ZKB Larry Biegelsen - Wells Fargo Matthew Mishan - KeyBanc Capital Markets Matt Miksic - C...
Alcon press release (NYSE:ALC): Q1 Non-GAAP EPS of $0.68 beats by $0.15. Revenue of $2.18B (+14.1% Y/Y) beats by $120M. 18% increase on a constant currency basis. Outook: The company now expects constant currency net sales growth to range between +9% to +11% vs. prior outlook of +7% to +9%. R...
Strong quarterly sales of $2.2 billion, up 14% or 18% constant currency Double-digit growth in net sales in both Surgical and Vision Care Updated 2022 full year outlook Ad Hoc Announcement Pursuant to Art. 53 LR Alcon (SIX/NYSE:ALC), the global le...
News, Short Squeeze, Breakout and More Instantly...
Combined vitreoretinal-cataract system (VCS) and standalone cataract system (CS) are cleared for use in the U.S. New, proprietary technologies designed to deliver transformative surgical innovation Alcon to immediately begin collecting real-world user experience in the U.S. prior ...
2024-06-09 17:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Shares of Alcon Inc. (NYSE: ALC) traded at a new 52-week high today and are currently trading at $91.69. So far today, approximately 136.09k shares have been exchanged, as compared to an average 30-day volume of 907.93k shares. Alcon Inc., an eye care company, researches, develops, manufactur...